NCT04509947View on ClinicalTrials.gov

A Study of Ad26.COV2.S in Adults (COVID-19)

PHASE1CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

August 11, 2020

Primary Completion Date

February 22, 2021

Study Completion Date

November 16, 2021

Conditions
Healthy
Interventions
BIOLOGICAL

Ad26.COV2.S

Ad26.COV2.S will be administered as IM injection at 2-dose (high and low) levels.

BIOLOGICAL

Placebo

Placebo will be administered as IM injection.

Trial Locations (3)

812-0025

Souseikai Hakata Clinic, Fukuoka

SOUSEIKAI PS Clinic, Fukuoka

813-0017

Souseikai Fukuoka Mirai Hospital, Fukuoka

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT04509947 - A Study of Ad26.COV2.S in Adults (COVID-19) | Biotech Hunter | Biotech Hunter